One of them, in APOE, is already known to be associated with CSF tau and Aβ42 ( Kauwe et al., 2007, 2008, 2011; Cruchaga et al., 2010, 2011) as well http://www.selleckchem.com/products/Temsirolimus.html as risk for AD. The other three are novel loci. The top hit for CSF tau (rs9877502; 3q28) also exhibited association with risk for AD (p = 2.67 × 10−4), tangle pathology (p = 0.01), and global memory decline (p = 4.86 × 10−5). SNPs in the 6q21.1 locus are in the TREM gene cluster close to TREM2, a gene in which a rare variant has recently

been reported to substantially increase risk for AD ( Guerreiro et al., 2012). The other genome-wide significant locus identified in this study did not show association with risk for disease, tangle pathology or memory decline. The lack of association

www.selleckchem.com/products/SRT1720.html with other AD phenotypes could be because these SNPs have a weaker impact on these phenotypes, or because they affect other aspects of AD, such as disease duration or age at onset. Alternatively, the sample size for the data sets used in the pathology and memory decline studies may not provide enough statistical power. Overall, these results illustrate how genetic studies of disease endophenotypes are an effective approach for identifying disease risk loci that is complementary to case-control association studies. CSF tau, ptau, and Aβ42 were measured in 1,269 individuals. There were 501 samples from research participants enrolled in longitudinal studies at the Knight-ADRC, 394 in ADNI, 323 in studies at the University of Washington (UW), and 51 in studies in University of Pennsylvania (UPenn). CSF collection and Aβ42, tau, and ptau181 measurements were performed as described previously (Fagan et al., 2006). Table 1 shows the demographic data and description of the CSF biomarkers in each data set. The samples were genotyped using Illumina chips. Cases received

a diagnosis of dementia of the Alzheimer’s type (DAT), using criteria equivalent to the National Institute of Neurological and Communication PAK6 Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association for probable AD (McKhann et al., 1984). Controls received the same assessment as the cases but were nondemented. All individuals were of European descent and written consent was obtained from all participants. While there are differences in the absolute levels of the biomarker measurements between the studies that likely reflect differences in the methods used for quantification (regular ELISA versus Luminex), ascertainment, and/or in handling of the CSF after collection, CSF ptau levels in the Knight-ADRC, ADNI, UW, and UPenn samples show similar characteristics (Table S1). CSF ptau and tau show a 10-fold difference between individuals in each data set and have similar covariates in each data set. The Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP) recruit participants without known dementia who agree to annual clinical evaluations and sign an Anatomic Gift Act donating their brains at death.